Table 1.
Baseline Characteristics of the REACH and SMART Populations
| REACH Western Europe (n=14 259) | SMART Cohort (n=6959) | REACH North America (n=19 170) | |
|---|---|---|---|
| Age, y | 68 (10) | 60 (10) | 70 (10) |
| <55 y | 1481 (10) | 2093 (30) | 1658 (9) |
| 55 to 65 y | 3525 (25) | 2382 (34) | 4325 (23) |
| 65 to 75 y | 5509 (39) | 2005 (29) | 6413 (33) |
| ≥75 y | 3744 (26) | 479 (7) | 6774 (35) |
| Male sex | 10 270 (72) | 5098 (73) | 11 861 (62) |
| Current smoking | 2283 (16) | 2195 (32) | 2546 (13) |
| Systolic blood pressure, mm Hg | 140 (18) | 140 (21) | 132 (18) |
| Diastolic blood pressure, mm Hg | 80 (10) | 81 (11) | 75 (11) |
| Diabetes mellitus | 4771 (33) | 1227 (18) | 8118 (42) |
| Cardiovascular history | |||
| Congestive heart failure | 2208 (15) | ··· | 3692 (19) |
| Atrial fibrillation | 1629 (11) | 79 (1) | 2605 (14) |
| Coronary artery disease | 9860 (69) | 4367 (63) | 15 512 (81) |
| Cerebrovascular disease | 4451 (31) | 2124 (31) | 5348 (28) |
| Peripheral artery disease | 3343 (23) | 1377 (20) | 2329 (12) |
| Laboratory values | |||
| Total cholesterol, mmol/L | 5.1 (1.2) | 4.8 (1.2) | 4.6 (1.1) |
| Creatinine, μmol/L | 93 (28) | 88 (77) | 100 (35) |
| Medication use | |||
| Statin | 10 176 (71) | 4683 (67) | 14 787 (77) |
| Acetylsalicylic acid | 9529 (67) | 4022 (68) | 14 459 (75) |
| Antihypertensive medication | 12 900 (90) | 5183 (74) | 17 933 (94) |
All data are displayed as mean (standard deviation) or n (%). REACH indicates Reduction of Atherothrombosis for Continued Health; SMART, Secondary Manifestations of Arterial Disease.